GSK and Dr Reddy's form alliance for emerging markets
This article was originally published in Scrip
Large innovator companies continue to tap leading Indian firms as they target emerging markets for growth in the short-term. GlaxoSmithKline and Dr Reddy's Laboratories are the latest to enter into an alliance to develop and market a basket of products across a large number of emerging markets, excluding India.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.